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Abstract
Background: The nature of parotid tumors often remains unknown preoperatively
and final histopathology may reveal unexpected malignancy. Still, the use of fine-nee-
dle aspiration cytology (FNAC) and imaging varies in the management of these
tumors.
Methods: We evaluated the preoperative examinations and management of all 195
parotid gland tumors diagnosed within our catchment area of 1.6 million people dur-
ing 2015.
Results: Altogether 171 (88%) tumors were classified as true salivary gland neo-
plasms. FNAC showed no false malignant findings, but it was false benign in 5 (2.6%)
cases. Preoperative MRI was utilized in 48 patients (25%). Twenty (10%) malignancies
included 16 salivary gland carcinomas. Pleomorphic adenomas accounted for 52% of
all adenomas. For 24 (40%) Warthin tumors, surgery was omitted.
Conclusion: The proportion of malignancies was lower than generally presented. Our
proposed guidelines include ultrasound-guided FNAC with certain limitations. MRI is
warranted in selected cases, but seems unnecessary routinely.
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1 | INTRODUCTION
Parotid gland tumors constitute around 70% of all salivary gland
tumors, and historic reports state that approximately 80% of them
are benign.1,2 A recent study reported that the incidence of salivary
gland cancer has been increasing through 1973 to 2009, most com-
monly in the parotid gland, although the causes still remain
unknown.3 The latest World Health Organization (WHO) classifica-
tion (2017) includes 11 different benign and 20 malignant salivary
gland tumor types,4 which highlights the need to centralize their
challenging management.
Differentiation between benign and malignant salivary gland
tumors by clinical examination is often impossible. Successful out-
come of parotid surgery warrants careful pre- and perioperative plan-
ning and decision making, since final histopathology may reveal
unexpected malignancy. Further, inadequate surgery may lead to
recurrences of even benign tumors, for example, pleomorphic adeno-
mas (PAs) that can be very difficult to manage. The current imaging
methods are not reliable enough for solid diagnosis and thus only
guide management. Ultrasound (US) combined with fine-needle aspi-
ration cytology (FNAC) should be adequate for the evaluation of
parotid tumors that are considered benign by clinical means,5 and
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computed tomography (CT) or magnetic resonance imaging (MRI) are
recommended for deep lobe tumors and whenever a malignancy is
suspected.6 MRI is a preferred imaging method because of its higher
contrast of soft tissues.7,8
The difficulties in distinguishing the tumor type preoperatively
makes proper surgical planning especially demanding. Obviously,
malignant parotid tumors require more extensive surgery than benign
neoplasms even though this anatomic location does not allow wide
resection margins. Limited extent of surgery, for example,
extracapsular dissection, is favored at many institutions when the
tumor is expected to be benign,9 and some selected tumors may be
managed by follow-up only. Preoperative knowledge of the most
likely histologic subtype would guide treatment since in some low-
grade carcinomas, extended parotidectomy can be avoided.10 The
high rate of cervical lymph node metastases in high-grade and
advanced-stage tumors warrants elective neck dissection (ND).
Proper primary management of parotid gland tumors demands
guidelines and optimization of treatment. Consideration between fol-
low-up only for selected patients, and the extent of surgical treatment
require reliable methods for diagnostic evaluation. Therefore, we
examined the incidence of different parotid gland tumor types and
evaluated all parotid gland tumors at our institution diagnosed over a
1-year period and focused on their diagnostic challenges and preoper-
ative evaluation. This work aims at offering some recommendations
to better delineate their management.
2 | PATIENTS AND METHODS
Our study included all patients with a suspicion or diagnosis of
a parotid gland tumor during the year 2015 at the Department of
Otorhinolaryngology—Head and Neck Surgery, Helsinki University
Hospital. We did not include patients who had surgery of the parotid
gland due to a known other neoplasm, such as malignancy of the
skin. In 2015, the 2005 WHO classification of tumors was in use.11
We reviewed the demographics, preoperative examinations, and
surgical treatment. We also analyzed patients, who did not undergo
surgery but who were diagnosed a neoplastic lesion of salivary
gland origin by cytology. The original FNAC analysis was performed
by several pathologists working in five different laboratories in
Southern Finland. Re-evaluation of the cytological findings from
carcinomas for this study was performed by an experienced patholo-
gist in salivary gland tumors (JT). The outcome of all patients without
surgical treatment and those with malignancy were reviewed after
March 2019.
In addition, we analyzed the population-based incidence of all
parotid gland neoplasms in Southern Finland, that is, in our univer-
sity hospital catchment area, covering a population of 1.6 million
people. In our series, we had two patients outside the catchment
area who had a malignant tumor. Further, during the study period 2
benign tumors had been operated in the private sector and were not
included in our series due to the lack of detailed data. However,
these two benign cases were included in the population-based inci-
dence rates.
We used SPSS 22.0 (SPSS, Chicago, Illinois) to perform the statis-
tical analysis. Student t test was used to establish statistical signifi-
cance of differences between the two independent groups. A P value
<.05 was considered statistically significant.
This was a single institution retrospective study, and an institu-
tional study permission was granted (HUS/§63/66/2018).
3 | RESULTS
Altogether 195 patients met the inclusion criteria. The mean age for
the cohort was 60.0 years (range, 15-94). Patients with a malignancy
were significantly older than those with a benign tumor (P = .001;
mean difference 11.4 years; 95% confidence interval, 4.6 to 18.2;
Table 1). Of the 195 patients, 171 (88%) underwent surgery, and 24
patients with a cytologically confirmed neoplastic lesion were
followed up only.
3.1 | Tumor distribution
According to the current WHO classification,4 171 were classified as
tumors of salivary gland origin (153 adenomas, 16 carcinomas,
1 lipoma, and 1 MALT lymphoma; Table 2). The rest 24 were other
type of lesions, including for example, 15 lymphoepithelial cysts.
Of the 171 “true” salivary gland tumors (by histopathological WHO
classification) 154 (90%) were benign and 17 (10%) malignant
(16 carcinomas, 1 MALT lymphoma). Of the whole series of 195
patients, 20 (10%) had a malignant tumor. Pleomorphic adenoma (PA)
was the most common epithelial neoplasm (80/169; 47%) followed
by Warthin tumor (60/169; 36%). One patient with PA had a recur-
rent PA (RPA): the previous tumor had been operated elsewhere
13 years earlier.
Of the 16 malignant parotid carcinomas, salivary duct carcinoma
(SDC) was the most common histological type (n = 5; 31%), followed
by acinic cell carcinoma (ACiC; n = 3; 19%). One patient with a histo-
pathologically confirmed squamous cell carcinoma (SCC) underwent
thorough preoperative examinations to exclude any other primary
tumor.
Four other malignant tumors in addition to carcinomas included
one MALT lymphoma, and two other lymphomas in patients who had
no other lesions than the parotid mass. Furthermore, one patient
underwent parotid surgery, and the histopathology revealed that the
intraglandular tumor was most likely an extension or a metastasis
from adjacent skin although no cutaneous lesion was observed.
3.2 | Clinical presentation
The initial clinical finding was a visible or palpable mass at the parotid
site in 189 patients, and two presented with parapharyngeal swelling.
However, 30 of these patients had an incidental finding on MRI, CT,
or US which were performed for other medical reasons. The most
common incidental finding was a Warthin tumor (n = 12).
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Facial dysfunction was observed in five patients: the final histopa-
thology was malignant in three cases, and one had had previous sur-
gery (RPA). In one patient, the dysfunction was mild and reversible,
and the tumor turned out to be a cyst.
Other clinical signs among patients with carcinoma included
growth through or into the skin (n = 1), palpable lymph nodes
(n = 3; all pN+), and suspicious lymph nodes on palpation (n = 2;
both pN0).
TABLE 1 Patient characteristics
Benign salivary gland
neoplasms (n = 153)
Malignant salivary gland
neoplasms (n = 16) All other lesions (n = 26) Total (n = 195)
Age
Mean (y) 58.8 (SD 14.6) 71.9 (SD 13.8) 59.2 (SD 13.2) 60.0 (SD 14.7)
Range (y) 15-94 45-92 33-86 15-94
Sex
Male (%) 70 (46) 9 (56) 13 (50) 92 (47)
Female (%) 83 (54) 7 (44) 13 (50) 103 (53)
TABLE 2 Tumor characteristics (n = 195)
Benign salivary gland neoplasms (n = 153) Number Percentage of all tumors
Percentage of the benign salivary
gland neoplasms
Pleomorphic adenoma 80 41.0 52.3
Warthin tumora 60 30.8 39.2
Basal cell adenoma 8 4.1 5.2
Oncocytoma 3 1.5 2.0
Myoepitelioma 2 1.0 1.3
Malignant salivary gland neoplasms (n = 16) Number Percentage of all tumors
Percentage of the malignant salivary
gland neoplasms
Salivary duct ca 5 2.6 31.3
Acinic cell ca 3 1.5 18.8
Mucoepidermoid ca 2 1.0 12.5
Ca ex pleomorphic adenoma 1 0.5 6.3
Squamous cell ca 1 0.5 6.3
Epithelial-myoepithelial ca 1 0.5 6.3
Large cell ca 1 0.5 6.3
Lymphoepithelial ca 1 0.5 6.3
Polymorphous low-grade adeno ca 1 0.5 6.3
Benign soft tissue lesions (n = 1) Number Percentage of all tumors
Lipoma 1 0.5
Haematolymphoid tumors (n = 3) Number Percentage of all tumors
MALT lymphoma 1 0.5
Other lymphomas 2 1.0
Other lesions (n = 22) Number Percentage of all tumors
Lymphoepithelial cyst 15 7.7
Degenerative changes; no diagnostic changes 2 1.0
Neurofibroma 1 0.5
Solitary fibrous tumor 1 0.5
Oncocytic hyperplasia 1 0.5
Granulomatous lesion 1 0.5
Metastasis (squamous cell ca; skin)b 1 0.5
Abbreviation: ca, carcinoma.
aTwenty-four were confirmed by cytology only.
bCutaneous origin was not known preoperatively; contact to the skin verified on histopathology.
696 ARO ET AL.
Altogether, 22 patients reported pain. Of them 16 had a benign
tumor (PA, n = 4; Warthin tumor, n = 9; cyst, n = 3) and six had a
malignancy. No statistical difference between the groups was
observed.
3.3 | US-guided FNAC
US was performed on 190 patients (97%), and all but five of them (ie,
97% of patients with a benign tumor and 95% of patients with a
malignant tumor) received FNAC under US guidance. In 15 patients
FNAC was repeated a second time due to an inadequate sample (class
0). Of the total patient cohort of 195 patients, needle biopsy with or
without US was not performed for six patients: one patient had SDC
and an ulcerating tumor through the skin, one had had open biopsy
taken elsewhere from the parapharyngeal mass, and other four
patients who had also a parapharyngeal tumor, and whose histopa-
thology revealed PA, had undergone MRI only. FNAC was performed
with palpation only for four patients. Table 3 presents the results of
all the 165 patients whose cytological finding was confirmed by
histology.
All six tumors from which FNAC revealed a highly suspicious
(class IV) or an obvious malignant (class V) lesion were also malignant
on final histopathology, yielding a specificity of 100%. FNAC revealed
a slight suspicion of malignancy (class III) in 12 tumors, of which 50%
(n = 6) turned out to be malignant, and 50% (n = 6) benign on histol-
ogy. Of the 138 FNACs (class I-II) showing a benign finding 5 (4%)
were malignant on histology (Table 4 [patients 1-5]). Of these five
cases, clinical examination, US and MRI revealed signs of malignancy
in one patient (patient no. 4 in Table 4) necessitating more radical sur-
gical treatment, but in four other patients, malignancy was not
suspected before histopathological examination.
Altogether 74 FNAC samples showed signs of PA, and 70 (95%)
of them proved to be correct. FNAC showed signs of a Warthin
tumor in 54 cases, of which 24 were followed up and the rest 30
were histologically all confirmed as Warthin tumors. Additionally, in
one other sample the possibility of Warthin tumor was speculated.
This case was false malignant (Table 4, patient 4). Preoperatively,
FNAC was reported as a cyst in 20 tumors, of which five turned out
to be neoplasms (Warthin tumor, n = 2; oncocytoma, n = 1; PA,
n = 1, and low-grade mucoepidermoid carcinoma), and 15 were non-
neoplastic cysts.
The re-evaluation of the cytological findings from carcinomas is
presented in Table 4. Re-evaluation showed that of the five false
benign cytologic findings three showed signs raising suspicion of
malignancy (class 3).
3.4 | US, MRI, and CT
In imaging, all lymph nodes appeared as normal in benign conditions.
Of the six patients with pN+, three had palpable lymphadenopathy,
and US raised signs or suspicion of abnormal lymph nodes in four.
MRI did not reveal any further abnormal lymph nodes. MRI was uti-
lized altogether in 48 patients (for 38 patients with a benign tumor
and for 10 patients with a malignancy on histopathology). This imag-
ing modality offers some advantages over US due to its serial imaging
sections and possibility for later interpretation. In those five patients,
who did not have US and FNAC, MRI was the only imaging modality:
all had PAs extending to the parapharyngeal space. Seven patients
underwent CT: two with a PA and five with a malignant tumor in his-
topathology. In these cases, the reason for choosing CT over MRI was
probably due to patient-related factors, for example, contraindication
for MRI or inability to stay still for a longer period.
When compared with the FNAC, MRI was used in 7 (78%) of the
class 0 cases, in 24 (17%) of the class I and II cases, in 5 (42%) of the
class III cases, and in 4 (67%) of the class IV and V cases.
3.5 | Adenomas
The mean size of the adenomas that were operated was 23 mm
(range, 6-70). One of the patients with a histologically confirmed RPA
underwent radical parotidectomy with mastoidectomy. Rest of the
patients were operated either with partial or superficial parotidectomy
(n = 131), including the patients with parapharyngeal tumors, or
extracapsular dissection (n = 24).
Altogether 24 patients who were diagnosed having a Warthin
tumor by cytology did not undergo surgery but were followed up only.
Twelve (50%) of these were incidental findings detected on imaging
due to various other reasons. Because the patients had no symptoms
and diagnosis was regarded reliable enough, surgery was omitted.
Patients were advised to contact our department in case symptoms
emerged in follow-up. Three years later one patient underwent sur-
gery because the tumor had grown and caused pain. Additionally, two
patients visited the outpatient clinic once, but surgery was not reg-
arded necessary.
3.6 | Carcinomas of salivary gland origin
The mean diameter of the 16 salivary gland carcinomas was 26 mm
(range, 10-60). Two patients underwent radical parotidectomy, six
total parotidectomy, seven partial or superficial parotidectomy, and
one extracapsular dissection. Eleven (11/16; 69%) of the patients
TABLE 3 Comparison of cytology and histopathology (n = 165)
Histology
Cytology (class) Benign Malignant
0 (inadequate) 7 2
I-II 133 5
III 6 6
IV 0 1
V 0 5
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underwent some degree of ND: level II (n = 3), levels II to III (n = 2),
levels II to V (n = 2), levels I to IV (n = 1), and levels I to V (n = 3).
The pathological T classifications were as follows: T1, n = 8
(50%); T2, n = 3 (19%); T3, n = 2 (13%); and T4, n = 3 (19%). Histologi-
cal examination revealed metastatic lymph nodes (pN+) in six patients.
Ten (63% of salivary gland carcinomas) patients had no metastatic
lymph nodes, either in their ND specimen (n = 5) or clinically (n = 5;
no ND, including follow-up).
After the final histopathological diagnosis, the multidisciplinary
tumor board concluded that one patient required additional surgery
on the neck without delay due to the type of histology (high-grade
ACiC). However, the ND specimen from the second surgery did not
reveal any metastatic lymph nodes. Distant metastasis was detected
immediately after diagnosis in one patient with SDC.
Postoperative radiotherapy (RT) was given to five patients and
chemoradiotherapy (CRT) to two patients with a malignant tumor.
The follow-up of the 16 patients with carcinomas is presented in
Table 4. During follow-up two patients developed distant metastases.
3.7 | Other lesions
Twenty-two other lesions included 15 non-neoplastic cysts with a mean
diameter of 21 mm (range, 7-40). Preoperative imaging (US, n = 15;
MRI, n = 4) had raised suspicion of a neoplasm in two of the cysts.
3.8 | Population-based incidences
The population-based analysis showed that within the catchment area
there were 171 tumors classified as salivary gland origin (by WHO
classification), including 156 benign and 14 malignant neoplasms,
yielding an annual incidence of 9.8/100000 inhabitants for benign
neoplasms and 0.88/100000 inhabitants for malignant neoplasms.
4 | DISCUSSION
This study covers all parotid gland tumors diagnosed within a popula-
tion area of 1.6 million people in Southern Finland during a 1-year
period. Malignant parotid gland tumors represented 10% of all neo-
plasms, which is in line with the study published by Bradley et al in
201312 but significantly less than in some other recent studies
reporting 14% to 32%.13-17 Due to the national health care system
with centralized treatment we were able to gather a patient series
that represents the true distribution of benign and malignant tumors
within our geographic area. We report an annual incidence of 0.88/
100 000 inhabitants for malignant parotid neoplasms, which follows
the estimation presented previously from the UK.12 PAs typically
cover two thirds of the benign tumors of the salivary glands,11 but
only 47% of the benign epithelial tumors in the present study. In addi-
tion, 36% were Warthin tumors, which is significantly more than in
other series (8%-15%),15,17 but reflects figures presented by Perkins
et al.18 Most malignant tumors in our study were SDCs (31%), a signif-
icantly differing finding from other studies where other tumor types
predominate.13,14,16,19 We encountered no adenoid cystic carcinomas
(ACC), but noteworthy, the overall number of malignancies remained
low. In our previous study of submandibular gland neoplasms, ACC
was the most common type of malignancy.20
US was performed on most patients (97%), and only for five with-
out a simultaneous FNAC. In the present study, the rate of false
benign and malignant finding reported from FNAC are well in line with
the current literature,15,17,21,22 and we had no false malignant findings
(class IV and V). Although a repeated FNAC sample was obtained in
15 (8%) patients, the FNAC remained inadequate (class 0) in 5% of the
patients, which compares well with other series with figures ranging
between 6% and 7%.13,15,17 The proportion of inconclusive or inade-
quate cytological samples and lack of accuracy of grading for malig-
nant tumors remains a challenge in management planning.
Recently, a new cytological classification for salivary gland tumors
has been launched.23 The Milan classification includes six different
diagnostic categories, which incorporate cytopathology, risk of malig-
nancy, and treatment recommendations. For this study, we re-ana-
lyzed cytological samples from the 16 malignant neoplasms although
their malignant nature was evident at that time. Nevertheless, the key
issue still remains: is the lesion non-neoplastic, a benign adenoma or
malignant.
Certain cytological findings, such as those showing PA, are consid-
ered highly reliable with a correct diagnosis in 91% to 94% of
cases.14,20,24 Somewhat less reliable figures have also been presented:
We found previously that 10% of submandibular gland tumors with a
benign cytology turned out malignant,20 and Suzuki et al14 showed this
risk to be even 14% in parotid tumors. Thus, a risk for malignancy
remains: in our series, one such tumor turned out to be carcinoma ex PA.
In the present series, 5 (4%) patients who had a false benign
FNAC from their malignant tumor warrant special attention. In four of
them, malignancy was diagnosed unexpectedly. Re-evaluation of the
cytology of these five cases showed no signs of malignancy in two
and error in interpretation in three. Class III will require special caution
as in 50% (n = 6/12) of these cases the tumors turned out to be malig-
nant. It is common for the radiologists who take the FNAC under US
guidance to use a 22-gauge needle. Recent data have shown the
superiority of US-guided core-needle biopsy (CNB) compared with
FNAC especially in increasing the sensitivity to 95% in detecting a
malignancy.25 This practice might enable more specific histological
tumor typing preoperatively,26 and even molecular testing.27,28 These
reports indicate that using a larger needle would minimize the number
of inadequate samples and increase the quality of the method. Fur-
ther, as salivary gland malignancies are rare and include various histo-
logical types, we recommend centralization of sample evaluation or
very low threshold level for consultations among pathologists. Espe-
cially when omitting surgery, for example, in elderly patients or in
patients who are in high risk for surgery, this practice to avoid false
FNAC findings would be of utmost importance. Frozen section analy-
sis was not employed in our series, and based on the previous results,
CNB might replace this practice in selected cases.
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The incidence of Warthin tumors has increased steadily over the
years.29,30 The imaging modalities have improved, and more patients are
susceptible to have imaging for various reasons, leading to incidental
findings also in the parotid gland. In our cohort, 40% of patients (n = 24)
diagnosed with a Warthin tumor were omitted surgery because they
experienced no symptoms and diagnosis was regarded reliable enough
for this policy. In one patient, the cytological diagnosis had remained
speculative and was eventually malignant in histopathology. This raises
a question of appropriate indications to choose follow-up only. In prac-
tice, patients are well counseled to acknowledge the risks related to
parotid gland surgery,31 and when all cytological criteria for Warthin
tumor are fulfilled, the diagnosis is nearly 100%.14,32,33
We had 15 patients with a final histopathology showing a cyst.
This raises a question whether surgery was even beneficial for them.
A cytological finding of a cyst is a risk for false diagnosis and thus sur-
gery is indicated if a neoplasm is suspected. A study by Suzuki et al14
reported that 16% of nondiagnostic FNACs turned out as cysts and
Eytan et al17 showed that 21% of all false positive FNACs were cysts
in histopathology. In our series, two lesions with a FNAC indicative of
a cyst turned out as malignant.
In our cohort, MRI was utilized in 25% of cases, and either MRI or
CT was used in 75% of tumors that turned out malignant. MRI is supe-
rior to CT, especially in defining perineural spread,34,35 and we prefer
MRI at our institution for parotid tumors. MRI has a positive predictive
value of 96% for PA,36 and we had five patients with a suspicion of PA
in MRI who underwent surgery without any additional preoperative
information. The benefit of offering MRI for all patients remains uncer-
tain, although apparently some centers prefer this. We recommend pre-
operative MRI for all patients having class III, IV or V on FNAC, as it
could also help to guide treatment more effectively and also lymph node
status can be assessed and documented with higher certainty. Efforts to
minimize the occurrence of inadequate/inconclusive FNAC are required
but additional imaging might also prove of value in these cases. Perkins
et al stated that combining preoperative imaging significantly improves
the results of FNAC.18 We feel that when a lesion is regarded as benign
and if omission of surgery is planned, further imaging (MRI) and/or fol-
low-up seem advisable and informing the patient to contact the depart-
ment in case of new symptoms.
In benign parotid tumors, the extent of surgery should follow recom-
mendations based on the size and location of the tumor.37 Treatment
protocol for the neck in malignant cases remains unclear especially in
cases with a clinically negative neck (cN0), and the variety of histological
tumor types will cause further confusion. Due to the uncertainty of the
exact histology and grade of the tumor preoperatively or perioperatively,
some suggest elective ND for all salivary gland cancer patients.38 We sug-
gest ND for all those who have a cytology class of IV or V, or clinical signs
of malignancy, although in some cases, for example, with ACC,39 the need
still remains contradictory. The positive predictive value of malignant
cytology is high, as shown also in the present series. The extent of ND
should be tailored based on the findings on imaging and the likelihood of
tumor grade on cytology. Due to the variety of salivary tumors and vari-
ous postoperative treatment options, a detailed guideline for managing
these neoplasms will be beyond the scope of this study.
Each metastatic lymph node on the neck up to four confers a
34% increased risk of salivary gland cancer mortality.40 Still, the cur-
rent tumor staging systems do not account for the absolute number
of metastatic lymph nodes in salivary gland cancer, which might influ-
ence adjuvant treatment recommendations. Adjuvant RT is commonly
recommended in high-grade malignancies, and postoperative RT/CRT
was given in this series for 7 (44%) patients who had metastatic dis-
ease and/or a high-grade tumor. Although the addition of chemother-
apy shows no clear survival benefit, adjuvant RT improves survival if
negative prognostic factors exist.41
We find that US and FNAC should serve in the primary examina-
tion of parotid gland masses. If FNAC shows class III finding or malig-
nancy, or remains repeatedly inadequate, we recommend MRI.
Additional imaging is also advisable if the patient presents symptoms
or signs suggestive of a malignancy (eg, tumor with irregular borders,
enlarged lymph nodes, nerve deficits, or pain). In selective cases with
cytologically confirmed Warthin tumor, omitting surgery is a reason-
able option. These guidelines necessitate co-operation with the radiol-
ogist and pathologist, all of whom are expected to pose experience in
diagnosing salivary gland tumors. The rarity of all salivary gland
tumors warrants centralized management. We find that one of the
key issues to improve preoperative diagnostics is to refine cytology by
using large needles, pay attention to proper sampling technique, pref-
erably to obtain fragments for histological evaluation. Centralized
evaluation of the samples is also mandatory.
5 | CONCLUSION
The proportion of malignant parotid gland tumors was lower in our
material than in many other series. Our study supports the conception
that US combined with FNAC is a sufficient diagnostic method for
most parotid gland tumors. Whenever there is even the slightest sus-
picion of malignancy in US or FNAC, further imaging (MRI) with the
assessment of adjacent lymph nodes is mandatory. All efforts to elimi-
nate inadequate and inconclusive FNACs are imperative to better tar-
get treatment in the primary setting or when omitting surgery as the
therapeutic approach.
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